• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新疆地区汉族和维吾尔族冠心病患者经皮冠状动脉介入治疗后支架再狭窄的预测因素

Predictors of Stent Restenosis in Han and Uygur Patients with Coronary Heart Disease after PCI in the Xinjiang Region.

作者信息

Wang Jiao, Yang Yuchun, Zhang Lei, He Pengyi, Mu Huyati

机构信息

Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

出版信息

Cardiol Res Pract. 2022 Jul 31;2022:7845108. doi: 10.1155/2022/7845108. eCollection 2022.

DOI:10.1155/2022/7845108
PMID:35958295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9357810/
Abstract

BACKGROUND

Stent restenosis after PCI seriously affects the efficacy and prognosis; therefore, the study of ISR risk factors has become an urgent topic to be solved.

OBJECTIVE

To investigate the risk factors for in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) in Han and Uygur patients with coronary heart disease.

METHODS

The clinical data of 345 Han and 127 Uygur patients who underwent intracoronary stent implantation were divided into an ISR group and a non-ISR group. The general clinical data, laboratory indicators, and coronary artery lesions were compared.

RESULTS

Age (OR = 1.040, 95% CI: 1.006∼1.075), triglycerides (OR = 1.440, 95% CI: 1.050∼1.973), total cholesterol (OR = 5.256, 95% CI: 2.826∼9.773), and ApoB (OR = 137.540, 95% CI: 11.364∼899.455) were independent risk factors for ISR after PCI in the Han patients, while ApoAI (OR = 0.002, 95% CI: 0.001∼0.011), MCV (OR = 0.824, 95% CI: 0.744∼0.911), MCH (OR = 0.421, 95% CI: 0.324∼0.548), and MCHC (OR = 0.934, 95% CI: 0.903∼0.965) were protective factors of ISR after PCI in Han patients, and the logistic regression equation composed of various factors predicted that the area under the ROC curve of ISR was 0.905. ApoB (OR = 11.571, 95% CI: 1.667∼80.340), Gensini score (OR = 1.017, 95% CI: 1.003∼1.031), and diabetes history (OR = 3.474, 95% CI: 1.189∼10.151) were independent risk factors for ISR after PCI in Uygur patients, and the area under ROC curve of ISR predicted by logistic regression equation is 0.807. The predictive efficiency of the Gensini score and ApoB level for ISR in Uygur patients was higher than that in Han, while the predictive efficiency of levels of ApoAI and MCH for ISR in Han patients was higher than that in Uygur ( < 0.05).

CONCLUSION

The independent risk factors for ISR after PCI in Han and Uygur patients in Xinjiang are different.

摘要

背景

经皮冠状动脉介入治疗(PCI)后支架再狭窄严重影响疗效及预后,因此,研究支架内再狭窄(ISR)的危险因素已成为亟待解决的课题。

目的

探讨新疆汉族和维吾尔族冠心病患者PCI术后支架内再狭窄(ISR)的危险因素。

方法

将345例汉族和127例维吾尔族接受冠状动脉内支架植入术患者的临床资料分为ISR组和非ISR组,比较一般临床资料、实验室指标及冠状动脉病变情况。

结果

汉族患者PCI术后ISR的独立危险因素为年龄(OR = 1.040,95%CI:1.006~1.075)、甘油三酯(OR = 1.440,95%CI:1.050~1.973)、总胆固醇(OR = 5.256,95%CI:2.826~9.773)和载脂蛋白B(ApoB,OR = 137.540,95%CI:11.364~899.455),而载脂蛋白AI(ApoAI,OR = 0.002,95%CI:0.001~0.011)、平均红细胞体积(MCV,OR = 0.824,95%CI:0.744~0.911)、平均红细胞血红蛋白含量(MCH,OR = 0.421,95%CI:0.324~0.548)和平均红细胞血红蛋白浓度(MCHC,OR = 0.934,95%CI:0.903~0.965)是汉族患者PCI术后ISR的保护因素,由各因素组成的logistic回归方程预测ISR的ROC曲线下面积为0.905。维吾尔族患者PCI术后ISR的独立危险因素为ApoB(OR = 11.571,95%CI:1.667~80.340)、Gensini评分(OR = 1.017,95%CI:1.003~1.031)和糖尿病史(OR = 3.474,95%CI:1.189~10.151),logistic回归方程预测ISR的ROC曲线下面积为0.807。Gensini评分和ApoB水平对维吾尔族患者ISR的预测效率高于汉族,而ApoAI和MCH水平对汉族患者ISR的预测效率高于维吾尔族(P<0.05)。

结论

新疆汉族和维吾尔族患者PCI术后ISR的独立危险因素不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af3d/9357810/0619d99d1ad9/CRP2022-7845108.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af3d/9357810/d6b6b94818c2/CRP2022-7845108.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af3d/9357810/0619d99d1ad9/CRP2022-7845108.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af3d/9357810/d6b6b94818c2/CRP2022-7845108.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af3d/9357810/0619d99d1ad9/CRP2022-7845108.002.jpg

相似文献

1
Predictors of Stent Restenosis in Han and Uygur Patients with Coronary Heart Disease after PCI in the Xinjiang Region.新疆地区汉族和维吾尔族冠心病患者经皮冠状动脉介入治疗后支架再狭窄的预测因素
Cardiol Res Pract. 2022 Jul 31;2022:7845108. doi: 10.1155/2022/7845108. eCollection 2022.
2
A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis.预测经皮冠状动脉介入治疗患者支架内再狭窄风险的列线图:基于人群的分析
Int J Gen Med. 2022 Mar 3;15:2451-2461. doi: 10.2147/IJGM.S357250. eCollection 2022.
3
Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis.白细胞介素-6-572C/G 启动子多态性与血清水平与经皮冠状动脉介入治疗后再狭窄的关系。
Chin Med J (Engl). 2013 Mar;126(6):1019-25.
4
New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent.接受药物洗脱支架经皮冠状动脉介入治疗的糖尿病患者支架内再狭窄的新预测指标。
J Geriatr Cardiol. 2018 Feb;15(2):137-145. doi: 10.11909/j.issn.1671-5411.2018.02.011.
5
[The predictive value of epicardial adipose tissue and inflammatory factors for in-stent restenosis].[心外膜脂肪组织和炎症因子对支架内再狭窄的预测价值]
Zhonghua Yi Xue Za Zhi. 2019 Dec 17;99(47):3732-3736. doi: 10.3760/cma.j.issn.0376-2491.2019.47.011.
6
The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.经皮冠状动脉介入治疗患者支架内再狭窄的特征和危险因素:我们能做些什么。
BMC Cardiovasc Disord. 2020 Dec 4;20(1):510. doi: 10.1186/s12872-020-01798-2.
7
Risk factors associated with intra-stent restenosis after percutaneous coronary intervention.经皮冠状动脉介入治疗后支架内再狭窄的相关危险因素。
Exp Ther Med. 2021 Oct;22(4):1141. doi: 10.3892/etm.2021.10575. Epub 2021 Aug 9.
8
Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.二代药物洗脱支架置入术后三血管病变患者血运重建和支架内再狭窄的危险因素:回顾性分析。
BMC Cardiovasc Disord. 2021 Sep 17;21(1):446. doi: 10.1186/s12872-021-02259-0.
9
Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.影响冠心病经皮冠状动脉介入治疗后支架再狭窄的因素:基于 1 年随访的临床试验。
Med Sci Monit. 2019 Jan 8;25:240-247. doi: 10.12659/MSM.908692.
10
The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.血清内脂素预测药物洗脱支架内再狭窄的价值。
Clin Chim Acta. 2018 Apr;479:20-24. doi: 10.1016/j.cca.2018.01.004. Epub 2018 Jan 3.

引用本文的文献

1
Comparison of Gensini score and SYNTAX score for predicting in-stent restenosis in patients with coronary artery disease and drug-eluting stent implantation.比较Gensini评分和SYNTAX评分对冠状动脉疾病及药物洗脱支架植入患者支架内再狭窄的预测价值。
Sci Rep. 2025 Jan 7;15(1):1077. doi: 10.1038/s41598-025-85191-z.
2
Risk prediction model for in-stent restenosis following PCI: a systematic review.经皮冠状动脉介入治疗后支架内再狭窄的风险预测模型:一项系统评价
Front Cardiovasc Med. 2024 Aug 29;11:1445076. doi: 10.3389/fcvm.2024.1445076. eCollection 2024.
3
A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention.

本文引用的文献

1
Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement.冠状动脉疾病患者的低密度脂蛋白胆固醇水平:改善的机会
Cardiol Res Pract. 2022 Apr 27;2022:7537510. doi: 10.1155/2022/7537510. eCollection 2022.
2
Analysis of the Correlation Between the Ratio of Monocytes to High-Density Lipoprotein Cholesterol and in-Stent Restenosis in Patients with Premature Coronary Heart Disease.分析单核细胞/高密度脂蛋白胆固醇比值与早发冠心病患者支架内再狭窄的相关性。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221079334. doi: 10.1177/10760296221079334.
3
Coronary In-Stent Restenosis: Predictors and Treatment.
经皮冠状动脉介入治疗后支架再狭窄的临床、辅助检查和遗传因素的系统评价和生物信息学研究。
BMC Cardiovasc Disord. 2024 Jun 14;24(1):304. doi: 10.1186/s12872-024-03955-3.
冠状动脉支架内再狭窄:预测因素与治疗。
Dtsch Arztebl Int. 2021 Sep 24;118(38):637-644. doi: 10.3238/arztebl.m2021.0254.
4
Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.常规脂蛋白检测与载脂蛋白在心血管疾病预测中的比较。
Circulation. 2019 Aug 13;140(7):542-552. doi: 10.1161/CIRCULATIONAHA.119.041149. Epub 2019 Jun 20.
5
Iron: Its complicated.铁:情况很复杂。
J Heart Lung Transplant. 2017 Jul;36(7):718-719. doi: 10.1016/j.healun.2017.04.005. Epub 2017 Apr 19.
6
Late clinical outcomes for SeQuent please paclitaxel-coated balloons in PCI of instent restenosis and de novo lesions: A single-center, real world registry.SeQuent please紫杉醇涂层球囊用于支架内再狭窄和原发病变经皮冠状动脉介入治疗的晚期临床结果:一项单中心、真实世界注册研究。
Catheter Cardiovasc Interv. 2017 Feb 15;89(3):375-382. doi: 10.1002/ccd.26546. Epub 2016 Apr 26.
7
In-Stent Restenosis: Pathophysiology and Treatment.支架内再狭窄:病理生理学与治疗
Curr Treat Options Cardiovasc Med. 2016 Feb;18(2):10. doi: 10.1007/s11936-015-0433-7.
8
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).与欧洲糖尿病研究协会(EASD)合作制定的欧洲心脏病学会(ESC)糖尿病、糖尿病前期和心血管疾病指南:欧洲心脏病学会(ESC)糖尿病、糖尿病前期和心血管疾病特别工作组与欧洲糖尿病研究协会(EASD)合作制定。
Eur Heart J. 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30.
9
Coronary heart disease mortality in China: age, gender, and urban-rural gaps during epidemiological transition.中国冠心病死亡率:流行病学转变过程中的年龄、性别和城乡差距。
Rev Panam Salud Publica. 2012 Apr;31(4):317-24. doi: 10.1590/s1020-49892012000400008.
10
Long-term outcome of percutaneous coronary intervention: the significance of native coronary artery disease progression.经皮冠状动脉介入治疗的长期预后:原发性冠状动脉疾病进展的意义。
Clin Cardiol. 2011 Oct;34(10):588-92. doi: 10.1002/clc.20929. Epub 2011 Sep 19.